Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BALLkine-2
- Development stage
- Preclinical
- Lead developer
- Lemonex
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Peritumoral
01
Overview
BALLkine-2 is a nanoparticle-based formulation of recombinant human interleukin-2 (IL-2) designed for cancer immunotherapy. Developed by Lemonex, it utilizes porous nanoparticles to deliver IL-2 peritumorally, which significantly reduces systemic exposure and toxicity compared to conventional high-dose IL-2 therapy. This approach enhances intratumoral lymphocyte infiltration without promoting regulatory T cell (Treg) development and demonstrates synergistic effects with PD-1 blockade in preclinical melanoma models. The drug aims to provide durable tumor control with fewer doses and lower systemic side effects than standard IL-2 treatments[1][3][6].
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on BALLkine-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BALLkine-2.